anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Lung adenocarcinoma (LUAD), a type of non-small cell lung cancer (NSCLC), originates from not only bronchial epithelial cells but also alveolar type 2 (AT2) cells, which could differentiate into AT2-like cells. AT2-like cells function as cancer stem cells (CSCs) of LUAD tumorigenesis to give rise to adenocarcinoma. However, the mechanism underlying AT2 cell differentiation into AT2-like cells in LUAD remains unknown. We analyze genes differentially expressed and genes with significantly different survival curves in LUAD, and the combination of these two analyses yields 147 differential genes, in which 14 differentially expressed genes were enriched in cell cycle pathway. We next analyze the protein levels of these genes in LUAD and find that Cyclin-A2 (CCNA2) is closely associated with LUAD tumorigenesis. Unexpectedly, high CCNA2 expression in LUAD is restrictedly associated with smoking and independent of other driver mutations. Single-cell sequencing analyses reveal that CCNA2 is predominantly involved in AT2-like cell differentiation, while inhibition of CCNA2 significantly reverses smoking-induced AT2-like cell differentiation. Mechanistically, CCNA2 binding to CDK2 phosphorylates the AXIN1 complex, which in turn induces ubiquitination-dependent degradation of β-catenin and inhibits the WNT signaling pathway, thereby failing AT2 cell maintenance. These results uncover smoking-induced CCNA2 overexpression and subsequent WNT/β-catenin signaling inactivation as a hitherto uncharacterized mechanism controlling AT2 cell differentiation and LUAD tumorigenesis.
The present invention relates to a snake venom capsule for treating brain cancer and a preparation method thereof. The capsule is prepared from bungarotoxin powder, monarch snake powder, rice field eel powder and more than tens of traditional Chinese herbal medicine according to certain proportion by procedures of decoction, filtration, grinding, mixing, agitation, sifting, etc. Cytotoxin in snake venom can be used for directly killing cancer cells, which has high inhibiting and killing rate, and lumps can be shrunk or disappear. The capacity of integrally enhancing immunological functions of the traditional Chinese medicine is used for indirectly inhibiting and killing the cancer cells. The activity of immune competent cells and immune factors is enhanced, the immunological functions are enhanced, and the growth and the extension of the cancer cells are resisted and inhibited by stimulating lymph cells to proliferate so as to reach the purpose of resisting cancer. The snake venom capsule has the advantages of convenient medicine administration, no toxic and side effect, sufficient medicine source, convenient collection, simple preparation, economy and practicality, and is a novel traditional Chinese medicine preparation for treating brain cancer, brain cancer transferring to lung cancer and lymph cancer.
The objectives of the proposed project are to examine the feasibility of delivering a combined yoga and MR intervention to VA patients with PTSD and cLBP and/or cNP within a randomized controlled trial study design. MR enhances the active yoga intervention for this specific population by providing a portable tool for managing stress and anxiety, and improving mental and emotional functioning in situations of daily life. The investigators will recruit and randomize 32 Veterans with PTSD to either enhanced yoga interventions or a relaxation/health education (R/HE) comparison intervention. The goal of the pilot randomized trial is to demonstrate the acceptability of the interventions, to study the feasibility of recruitment, retention, adherence, randomization, and assessments with military Veterans with PTSD, and to measure any adverse events. Data will inform plans for a full-scale effectiveness RCT.

Researchers and content experts will adapt and blend two manualized interventions (MR and yoga) into a single manualized and acceptable intervention. In addition, the existing yoga intervention and MR manuals will be adapted to provide a structured intervention guide for instructors. Next, the investigators will recruit and screen 32 Veterans with PTSD. Eligible participants will be randomized to either the enhanced yoga interventions or the (R/HE) comparison intervention. Assessments will occur at baseline, 12-weeks, and again 6-weeks after the intervention ends (18-weeks). The enhanced yoga intervention will consist of 1x weekly instructor-led yoga sessions lasting approximately 75 minutes, augmented by home practice of yoga for 20 minutes/day. The R/HE control intervention will be manualized and will meet weekly for 12 weeks for approximately 75 minutes per week. Short homework assignments will be included. The investigators will track and measure adverse events, recruitment rates, attendance and home practice rates, use of MR and yoga principles in daily life, attrition rates, and time to complete assessments. Questionnaires will assess pain-related function, pain, PTSD symptoms, insomnia/sleep, alcohol use, and quality of life. The investigators will also conduct qualitative interviews with 12 study participants to examine acceptability, recommendations, and factors affecting attendance and attrition. The investigators will target 7-8 yoga participants and 4-5 control participants. Data will be used to plan a full-scale RCT powered to detect differences in health outcomes.
In this study, the overall objective is comparison of progression of renal insufficiency in subjects with Advanced Diabetic Nephropathy (CKD stages 3 and 4) randomized into multifactorial intervention in the Diabetes-Renal Clinic (study group) and into usual care (control group). The multifactorial intervention includes the following: 1. Blood pressure control to the goal of \<130/80mmHg and renal protection with reduction of proteinuria to \<0.5g/day using a protocol that includes therapy with ACE inhibitors, ARBs or their combination. 2. Tight glucose control using SMBG and Lantus/Apidra self-escalation regimen. 3. Use of hypolipidemic therapy to achieve targets of LDL of \< 70 mg/dl, HDL \> 40/50 mg/dl (males/females) \[since you said that HDL is not a target because there are no meds for it I deleted HDL;\] and triglycerides of less than 200 mg/dl. 4. Patient enhanced self-management provided by combined diabetes-renal education curriculum (taught by certified diabetes and renal educators). 5. Behavior and social intervention (motivational interviews and social assessment) provided as needed by social workers. 6. Intense case management that includes close follow-up of visits, laboratory monitoring and other self-adherence behaviors. 7. Weight loss with lifestyle and diet modification.

Control Group will keep on receiving the usual treatment that they used to receive from their respective clinics and the Diabetes-Renal team would not alter their therapy or interfere in their management.
In vitro studies have shown ribavirin can reduce the phosphorylation of pyrimidine nucleoside analogues such as lamivudine and zidovudine. Although no evidence of a pharmacokinetic or pharmacodynamic interaction (e.g., loss of HIV-1/HCV virologic suppression) was seen when ribavirin was coadministered with lamivudine or zidovudine in HIV-1/HCV co-infected patients [see Clinical Pharmacology (12.3)], hepatic decompensation (some fatal) has occurred in HIV-1/HCV co-infected patients receiving combination antiretroviral therapy for HIV-1 and interferon alfa with or without ribavirin. Patients receiving interferon alfa with or without ribavirin and lamivudine and zidovudine tablets should be closely monitored for treatment-associated toxicities, especially hepatic decompensation, neutropenia, and anemia. Discontinuation of lamivudine and zidovudine tablets should be considered as medically appropriate. Dose reduction or discontinuation of interferon alfa, ribavirin, or both should also be considered if worsening clinical toxicities are observed, including hepatic decompensation (e.g., Child-Pugh greater than 6) (see the complete prescribing information for interferon and ribavirin). 

Exacerbation of anemia has been reported in HIV-1/HCV co-infected patients receiving ribavirin and zidovudine. Coadministration of ribavirin and zidovudine is not advised.
The application describes ceDNA vectors having linear and continuous structure for delivery and expression of a transgene. ceDNA vectors comprise an expression cassette flanked by two ITR sequences, where the expression cassette encodes a transgene. Some ceDNA vectors further comprise cis-regulatory elements, including regulatory switches. Further provided herein are methods and cell lines for reliable gene expression in vitro, ex vivo and in vivo using the ceDNA vectors. Provided herein are method and compositions comprising ceDNA vectors useful for the expression of an antibody or fusion protein in a cell, tissue or subject. Such antibodies or fusion proteins can be expressed for treating disease or alternatively, for the production of antibodies or fusion proteins in a commercial setting.
Subjects in the control group will be connected to the AnapnoGuard 100 control unit. In the control group, the cuff pressure control of the AnapnoGuard 100 control unit will be disabled (OFF). CO2 level above the cuff will be recorded. Suction and rinsing function will operate after the system detects no CO2.
This present invention discloses additive compositions for cosmetics, which comprises chitosan, nanodiamond and nano oxide particles (e.g. zinc oxide, titanium dioxide or the combination thereof). The chitosan is a high moisture, anti aqua and sterilization, which can avoid aqua in human body and cosmetic flow away. In addition, the chitosan is also a good matrix that can be attached by mineral, dyestuffs, sunscreen, dispersing nanoparticles and fragrance. Nano oxide particles are a good material for sunscreen, which can absorb UV light. Nanodiamond can be excited by UV light and emit Infrared which can proliferate collagen. The present invention also provides a cosmetic for preventing sunshine, keeping moisture, and emitting Infrared.
BACKGROUND AND AIM: Infertility in women has various causes, one of which is ovulation disorders. Polycystic ovary syndrome (PCOS) affecting ovulation is a complex idiopathic disease in which genetic polymorphisms may be involved. This study aimed to investigate the relationship between IL-6 -174 G/C and IL-1A -889 G/A cytokine polymorphisms with polycystic ovary syndrome in a population of Iranian women.
MATERIALS AND METHODS: In this case-control pilot study, 120 PCOS patients (60 infertile, LPI, and 60 women with recurrent pregnancy abortion, LPA) and 60 controls, CTRLs) participated. After genomic DNA extraction from peripheral blood, we investigated for the polymorphisms rs1800795 of the IL-6 -174 and rs1800587 of the IL-1A-889 using specific primers and PCR-RFLP followed by NlaIII enzyme digestion and PCR-ARMS techniques.
RESULTS: There was a significant difference in the studied groups in terms of clinical characteristics (p-value < 0.05) except for the levels of HDL and LDL. Regarding demographic and clinical characteristics of patients, a significant correlation was observed between C/G and G/G genotypes of rs1800795 and FBS level (p value = 0.002). Also, rs1800587 showed a substantial relationship between CC and CT genotypes with the level of LH in LPI and the level of FBS in the LPAs (p value = 0.04). There was no significant difference between the frequencies of rs1800795 and frequencies of rs1800587 genotypes in the three studied groups (p value > 0.05).The studied variants were in Hardy-Weinberg equilibrium.
CONCLUSION: The present work showed that rs1800795 and rs1800587 were not directly associated with PCOS in Iranian patients while the SNPs showed an indirect relationship with some factors affecting the disease. However, using genome-wide association analysis is a proper suggestion to obtain more reliable information about the disease's genetic view. To our knowledge, this is the first report that implicates the role of the examined SNPs in an Iranian PCOS population.
OBJECTIVES: I. Determine the efficacy of thalidomide in patients with steroid dependent or refractory chronic graft vs host disease following an allogeneic bone marrow transplant. II. Determine the toxicity of this regimen in these patients.

OUTLINE: This is a randomized study. Patients are stratified according to the type of bone marrow transplant received (allogeneic vs matched unrelated donor) and type of chronic graft vs host disease (steroid dependent vs steroid refractory). Patients receive either oral thalidomide or placebo 2-4 times a day for 6 months. The drug is then tapered until stopped. If disease recurs, the drug may be restarted for a second 6 month course. The maximum duration of treatment is 18 months. Patients continue on steroid therapy, which is tapered during study therapy. If no response is seen after 8 weeks, patients may cross over to the other alternate drug. Patients are followed weekly for 1 month, then every month for 1 year.

PROJECTED ACCRUAL: A total of 36 patients (18 per arm) will be accrued for this study.
Background Anal cancer disproportionately affects sexual and gender minority individuals living with HIV. High-resolution anoscopy (HRA) is an in-clinic procedure to detect precancerous anal lesions and cancer, yet prospective data on factors associated with HRA attendance are lacking. We examined whether anal HPV sampling at home versus in a clinic impacts HRA uptake and assessed HRA acceptability. Methods Sexual and gender minority individuals were randomised to home-based self-sampling or clinical sampling. All were asked to attend in-clinic HRA 1year later. We regressed HRA attendance on study arm using multivariable Poisson regression and assessed HRA acceptability using χ 2 tests. Results A total of 62.8% of 196 participants who engaged in screening attended HRA. Although not significant (P =0.13), a higher proportion of participants who engaged in clinic-based screening attended HRA (68.5%) compared to home-based participants (57.9%). Overall, HRA uptake was higher among participants with anal cytology history (aRR 1.40, 95% CI 1.07-1.82), and lower among participants preferring a versatile anal sex position versus insertive (aRR 0.70, 95% CI 0.53-0.91), but did not differ by race or HIV serostatus. In the clinic arm, persons living with HIV had lower HRA attendance (42.9%) versus HIV-negative participants (73.3%) (P =0.02) and Black non-Hispanic participants had lower HRA attendance (41.7%) than White non-Hispanic participants (73.1%), (P =0.04). No differences in attendance by race or HIV status were observed in the home arm. Conclusions HRA uptake differed significantly by race and HIV status in the clinic arm but not the home arm.
Hair care compositions and methods for using the same are disclosed herein. According to one aspect of the disclosure, a hair care composition is provided that includes from about 1 to about 20 wt. % of an anionic surfactant; from about 0.5 to about 5 wt. % of an amphoteric surfactant; from about 0.1 to about 7 wt. % of a nonionic surfactant; from about 0.1 to about 5 wt. % of a thickening agent, wherein the thickening agent is a natural gum; and from about 0.05 to about 4.5 wt. % of a silicone wherein the hair composition is an emulsion and all weight percentages are based on the total weight of the hair care composition. Additionally, the hair care composition may have a weight ratio for the total amount of anionic surfactant to the total amount of amphoteric surfactant that is about 5:1 to about 20:1.
Abuse Potential   
Morphine sulfate extended-release tablets contain morphine; an opioid agonist and Schedule II controlled substance with an abuse liability similar to other opioid agonists, legal or illicit [see Warnings and Precautions (5.1)]. Assess each patient’s risk for opioid abuse or addiction prior to prescribing morphine sulfate extended-release tablets. The risk for opioid abuse is increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depressive disorder). Routinely monitor all patients receiving morphine sulfate extended-release tablets for signs of misuse, abuse, and addiction during treatment [see Drug Abuse and Dependence (9)].

Life-Threatening Respiratory Depression   
Respiratory depression, including fatal cases, may occur with use of morphine sulfate extended-release tablets, even when the drug has been used as recommended and not misused or abused [see Warnings and Precautions (5.2)]. Proper dosing and titration are essential and morphine sulfate extended-release tablets should only be prescribed by healthcare professionals who are knowledgeable in the use of potent opioids for the management of chronic pain. Monitor for respiratory depression, especially during initiation of morphine sulfate extended-release tablets or following a dose increase. Instruct patients to swallow morphine sulfate extended-release tablets whole. Crushing, dissolving, or chewing the tablet can cause rapid release and absorption of a potentially fatal dose of morphine. 

Accidental Exposure   
Accidental ingestion of morphine sulfate extended-release tablets, especially in children, can result in a fatal overdose of morphine [see Warnings and Precautions (5.3)].
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely to anaesthesiology, and can be used as an anaesthesia care for surgeries, including oncotomy of various localisations. That is ensured by preoperative blood sampling in the amount 15 ml in a syringe with Solutio Glugicirum. Thereafter, dalargin 0.85 mcg/kg diluted in the same preservative is added in the syringe, and the prepared mixture is incubated at temperature 37C for 30-35 minutes. Immediately before the induction, an anaesthetic is added with 1/3 dose of dalargin with autoblood and verapamil in dosage 0.9 mcg/kg. It is followed with the anaesthetic induction with thiopental sodium, ketamine, dormicum. Before the traumatic stage, 1/3 dose of dalargin with autoblood and verapamil in dosage 0.9 mcg/kg are introduced. The most traumatic stages require thiopental sodium, propofol, dormicum, phentanyl to be introduced. 30-40 minutes prior to the surgery completed, 1/3 dose of dalargin with autoblood are introduced in combination with actovegin in dosage 5.6 mg/kg. ^ EFFECT: technique enables adequate analgesia during the whole intra- and postoperative period combined with reduced dosage of the administered narcotic analgesics due to the optimised circulatory system, activated stress limit processes and normalised neurovegetative body functions. ^ 2 tbl, 1 ex
PROBLEM TO BE SOLVED: To obtain a high-purity and stable crystal of an azole-based compound useful as a therapeutic agent for mycosis by crystallizing the compound according to a simple and specific method on an industrial mass scale. SOLUTION: This crystal of an azole-based compound represented by the formula, e.g. 2-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4- triazol-1-yl)propyl]-4-[4-(2,2,3,3-tetrafluoropropoxy)phenyl]-3-(2H,4H )-1,2,4- triazolone is a II type crystal having 127.3 deg.C melting point. The crystal has characteristic of having the peak at about 9 deg. diffraction angle in a powder X-ray diffractometry without any peak at about 6-6.5 deg. diffraction angle therein and further the endothermic peak at about 130 deg.C in a differential thermal analysis. The II type crystal is obtained by diluting a reactional mixture containing the compound represented by the formula with an organic solvent, carrying out the liquid separation operations three times and then crystallizing the compound in a system of an organic solvent-aqueous solution of a base once.
The coexistence of anti-glomerular basement membrane (anti-GBM) disease with thrombotic microangiopathy (TMA) is rarely encountered, and the clinical characteristics of this phenomenon are not well known.A 76-year-old Japanese woman with a history of idiopathic pulmonary disease was diagnosed with anti-GBM disease due to rapidly progressive glomerulonephritis and a positive anti-GBM antibody test result. We treated the patient with hemodialysis, glucocorticoids, and plasmapheresis. During treatment, the patient suddenly became comatose. TMA was then diagnosed because of thrombocytopenia and microangiopathic hemolytic anemia. The activity of a disintegrin-like and metalloproteinase with thrombospondin type 1 motif 13 (ADAMTS-13) was retained at 48%. Although we continued the treatment, the patient died of respiratory failure. An autopsy revealed the cause of respiratory failure to be an acute exacerbation of interstitial pneumonia. The clinical findings of the renal specimen indicated anti-GBM disease; however, there were no lesions suggestive of TMA. A genetic test did not reveal an apparent genetic mutation of the atypical hemolytic uremic syndrome.We conducted a literature review of past case reports of anti-GBM disease with TMA. The following clinical characteristics were obtained. First, 75% of the cases were reported in Asia. Second, TMA tended to appear during the treatment course for anti-GBM disease and usually resolved within 12 weeks. Third, ADAMTS-13 activity was retained above 10% in 90% of the cases. Fourth, central nervous system manifestations occurred in more than half of the patients. Fifth, the renal outcome was very poor. Further studies are required to understand the pathophysiology of this phenomenon.
PROBLEM TO BE SOLVED: To obtain a cosmetic sheet having high adhesiveness to the skin, free from disagreeable feeling, exhibiting high shape-retainability of cosmetic and uniformly peelable from the skin by using a hydrophilic sheet having a specific hardness. SOLUTION: This cosmetic sheet is a hydrophilic sheet having a hardness of 5,000-100,000gf/mm<2> . The material of the sheet is a polymer especially having hydroxyl group, ethylene oxide group or amide group (especially preferably starch or its derivative, particularly a starch wafer). The thickness of the cosmetic sheet is preferably 5-500μm. The cosmetic sheet can be used by applying a cosmetic to the skin and pasting the sheet to the applied part. As an alternative, the sheet is pasted to the skin after coating the sheet with a cosmetic or impregnating the cosmetic into the sheet.
The sham group receives 10 sessions of rTMS stimulation, once daily for 5 consecutive days a week. However, a sham stimulation coil is used, which emits the same sound and vibration as the active coil but does not produce any induced electrical currents.
Participants randomized to this arm will receive the Arm 4 processing fluency scorecard plus dynamic social norms messaging. Two messages will be sent during the intervention: The first message will contain the baseline refill score. The second message will note any changes in the refill score.
Sevoflurane was initiated, in both groups, at 8% for anesthesia induction until loss of consciousness was achieved, at which point it was discontinued. Following loss of consciousness ketamine was administered to Group SK (n=29) in the form of a 0.5mg/kg iv bolus. Patients in Group SS (n=30) received saline in the same manner.
PURPOSE: A cell apoptosis-inducing material and a method for inducing apoptosis using the same are provided to cheaply and quickly induce apoptosis of cells or tissues and to prevent disease by early diagnosis. CONSTITUTION: A composition for inducing cell senescence contains (R)-(-)-2,2-dimethyl-1,3-dioxolane-4-methanol of chemical formula 2. In chemical formula 2, R1 and R2 are independently H, R3 and R4 are independently methyl. The expression increase of intracellular caveolin is induced by introducing (R)-(-)-2,2-dimethyl-1,3-dioxolan-4-methanol into cells. The expression increase of the caveolin is measured through Western blotting. The apoptosis of mammal cells is induced by adding (R)-(-)-2,2-dimethyl-1,3-dioxolan-4-methanol into cells. The apoptosis induction is performed through microinjection, calcium phosphate co-precipitation, electroporation or cationic liposome utilization.